Introduction to Venetoclax And Ibrutinib Based Approaches In Cll
Exploring Venetoclax And Ibrutinib Based Approaches In Cll reveals several interesting facts. William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores
Venetoclax And Ibrutinib Based Approaches In Cll Comprehensive Overview
Kerry Rogers, MD, The Ohio State University, Columbus, OH, outlines the results of a three-year follow up of the Phase II trial ... Jacqueline Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, shares data from the Phase II ... William Wierda, MD, PhD, and an expert panel discuss the benefit of adding a CD-targeted monoclonal antibody to
The CAPTIVATE study results support using
Summary & Highlights for Venetoclax And Ibrutinib Based Approaches In Cll
- Carlo Croce, MD of The Ohio State University, Columbus, OH discusses drug combinations for
- Mitchell R. Smith, MD, PhD, discusses the use of
- During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to ...
- Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses updated data from a Phase II trial ...
- James N. Gerson, MD, discusses the phase III CLL14 trial evaluating the combination of
Stay tuned for more updates related to Venetoclax And Ibrutinib Based Approaches In Cll.